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Abstract: The trans-venous implantable cardioverter defibrillator (TV-ICD) is effective in treating
life-threatening ventricular arrhythmia and reduces mortality in high-risk patients. However, there
are significant short- and long-term complications that are associated with intravascular leads. These
shortcomings are mostly relevant in young patients with long life expectancy and low risk of death
from non-arrhythmic causes. Drawbacks of trans-venous leads recently led to the development of
the entirely subcutaneous implantable cardioverter defibrillator (S-ICD). The S-ICD does not require
vascular access or permanent intravascular defibrillation leads. Therefore, it is expected to overcome
many complications associated with conventional ICDs. This review highlights data on safety and
efficacy of the S-ICD and is envisioned to help in identifying the role of this device in clinical practice.
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1. Introduction
The implantable cardioverter defibrillator (ICD) represents the only effective therapy to prevent
sudden cardiac death (S-CD) in patients with structural heart disease or primary cardiac electrical
syndromes on optimal medical therapy [1–4].
ICD technology evolved throughout years from devices that were only able to treat ventricular
tachycardia or fibrillation (VT/VF) to modern systems that provide complex discrimination algorithms,
bradycardia-pacing support and resynchronization therapy. While effective and relatively safe,
transvenous ICDs (TV-ICDs) carry potential short- and long-term lead-related complications,
including those that are associated with the implant technique (pneumothorax, venous thrombosis,
hemopericardium, hemothorax) and those that are related to indwelling intracardiac leads (infections,
lead failure) [3,5].
Noticeably, long-term complications are increasing with longer ICD patients’ follow-up. Indeed,
it has been reported that lead failure occurs in up to 40% of transvenous leads eight years after
implantation [6]. Failure occurs more frequently in young patients, who expose the leads to greater
stress due to active life-style and longer life expectancy.
Moreover, long life expectancy is also associated with several pulse generator replacements and,
therefore, to an increased risk of pocket infection with potential lead involvement and bloodstream
dissemination [7]. Of note, failed and infected leads may need extraction, a complex procedure that is
associated with morbidity and even mortality [7].
Recently, the unmet need for an ICD without endovascular leads led to the development of an
entirely subcutaneous ICD (S-ICD).
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2. The S-ICD System
The S-ICD consists of a subcutaneous pulse generator that is covered in a titanium case and a
subcutaneous lead. The lead is composed of a proximal and a distal sensing electrode separated by
a 3-inch shock coil. The S-ICD has not capability for bradycardia or anti-tachycardia pacing (ATP),
but can deliver up to 30 s of post-shock transthoracic pacing [8]. The device has two programmable
zones of tachycardia detection: a conditional VT zone and a VF zone. In the conditional zone, complex
morphology-based algorithms discriminate VT/VF from supraventricular tachycardia (SVT), while in
the VF zone heart rate is the only criterion to determine whether the DC shock will be delivered or not.
3. S-ICD Implantation
The conventional S-ICD implantation is performed through three incisions: one on the left-lateral
chest for the pulse generator pocket, and two parasternal incisions that allow for lead tunnelization.
The first incision is over the fifth intercostal space between the mid and the anterior axillary lines, the
second incision is parasternal just below xiphoid process and the third one is parasternal, at the level of
the sternal notch. The pulse generator is positioned in a subcutaneous pocket created on the left lateral
chest. The electrode is tunnelled from the parasternal incision through the pocket site, and then should
lie parallel to the left side of the sternum, with its upper pole anchored at the level of the third incision.
S-ICD implantation is guided exclusively by anatomical landmarks, with the possibility to confirm
electrode and pulse generator position by fluoroscopy.
The superior parasternal incision is more susceptible to infection, more likely to cause discomfort
and may be aesthetically less acceptable than the other incisions. Therefore, a new implantation
technique (the “two incisions technique”) has been developed that avoid the third superior parasternal
incision by tunneling the defibrillation lead through a peel-away sheath introducer. The two-incision
technique can be alternatively used and demonstrated similar safety and efficacy as compared to the
three incision technique [9], and is currently the preferred implantation procedure. Recently, a shift
from the subcutaneous to an intermuscular device implantation has been proposed and is rapidly
gaining popularity. With the intermuscular approach, the S-ICD is placed in a virtual space between
the external surface of the serratus anterior and the anterior surface of the latissimus dorsi muscles,
offering the advantages of a better cosmetic outcome and the prevention of device damage during
physical activities and skin erosion [10].
Using the two sensing electrodes and the generator itself as the third one, three sensing vectors
are available to detect subcutaneous signals. The best vector is automatically selected by the system in
order to avoid double QRS counting and T-wave oversensing.
At the end of the procedure, VF is induced using 50 Hz current delivered by the device itself and
the 65 J defibrillation threshold (DFT) is assessed. After implantation, the S-ICD is programmed to
deliver only shocks at 80 J (Figure 1).
Unlike the TV-ICD, the defibrillation test is mandatory at present for S-ICD, as DFT may be more
dependent on system positioning. Nonetheless, as growing data show that defibrillation failure rates
with maximal energy output are comparable to the TV-ICD, the paradigm will likely shift away from
DFT testing.
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Figure 1. A 13 year old female patient with hypertrophic cardiomyopathy received an Subcutaneous 
implantable cardioverter defibrillator (ICD) (S‐ICD) for primary prevention of sudden cardiac death 
(S‐CD). The primary sensing vector was selected by the system and approved by the physician. One 
year  after  implantation,  the patient  experienced  an  episode  of  ventricular  fibrillation. The  figure 
shows the VF episode appropriately detected (T markers) and effectively treated by the S‐ICD with 
an 80 J shock (lightning marker). Time to therapy was 16.5 s. 
4. Screening and Eligibility 
Pre‐implant  surface  electrocardiogram  (ECG)  screening  is  needed  to  identify  patients  with 
unsuitable subcutaneous signals and a screening tool is used to confirm eligibility. 
Three electrodes are positioned in the same chest position of the S‐ICD lead distal and proximal 
sensing electrodes and  the pulse generator. ECG  recordings are collected  in  supine and  standing 
postures and are superimposed on a plastic ruler provided with template boxes. Either the maximal 
R or S waves of the QRS complex have to fit between the horizontal solid and dashed lines in any 
template box. T‐wave is required to fit within the boundaries of the template. A patient is considered 
suitable for S‐ICD if all of the QRS‐T complexes pass in any same lead supine and standing, at any 
gain, without changes of the R wave axis. In order to reduce subjectivity and increase efficiency, an 
automatic screening tool has recently been developed and equipped with a software that applies the 
same vector select algorithm and filters used by the S‐ICD to sense the cardiac signals.   
5. Safety 
Main  data  on  S‐ICD  safety  come  from  the  pooled  analysis  of  the  U.S.  IDE  study,the 
EFFORTLESS registry [11], and from the midterm outcomes analysis of the EFFORTLESS [12]. The 
pooled analysis assessed 882 patients during a 651 ± 345 days follow‐up [11], while in the extended 
follow‐up of the EFFORTESS cohort, 985 patients were evaluated with a mean follow‐up of 3.1 ± 1.5 
years [12]. Moreover, recently published registries analysed the performances of S‐ICD  in the real 
world  setting  and  evaluated  in‐hospital  and  short‐term  outcomes  among  thousands  of  S‐ICD 
recipients [13,14]. 
5.1. Infections 
The most common complication associated with S‐ICD implants is device infection. The pooled 
analysis of the IDE and EFFORTLESS studies reported a 2% device  infection, with 1.7% requiring 
explant/revision  [11].  When  complications  were  analysed  according  to  the  enrolment  period,  a 
decreasing  incidence  of  infections  with  increasing  operator  experience  has  been  observed  [15], 
which is consistent with a “learning curve”. The resulting reported global infection rate (2.4% over 
two years) was comparable to that of TV‐ICDs [16,17] (Tables 1 and 2). 
Figure 1. 13 year old fe ale patient ith hypertrophic cardio yopathy received an Subcutaneous
i plantable cardioverter defibrillator (I ) (S-I ) for pri ary prevention of sudden cardiac death
(S- ). The pri ary sensing vector as selected by the syste and approved by the physician. ne
year after implantation, the patient experienced an episode of ventricular fibrillation. The figure shows
the VF episode appropriately detecte (T markers) nd effectiv ly treated by the S-ICD with an 80 J
shock (lightning marker). Tim to therapy was 16.5 s.
4. Screening and Eligibility
Pre-implant surface electrocardiogram (ECG) screening is needed to identify patients with
unsuitable subcutaneous signals and a screening tool is used to confirm eligibility.
Three electrodes are positioned in the same chest position of the S-ICD lead distal and proximal
sensing electrodes and the pulse generator. ECG recordings are collected in supine and standing
postures and are superimposed on a plastic ruler provided with template boxes. Either the maximal
R or S waves of the QRS complex have to fit between the horizontal solid and dashed lines in any
template box. T-wave is required to fit within the boundaries of the template. A patient is considered
suitable for S-ICD if all of the QRS-T complexes pass in any same lead supine and standing, at any
gain, without changes of the R wave axis. In order to reduce subjectivity and increase efficiency,
an automatic screening tool has recently been developed and equipped with a software that applies
the same vector select algorithm and filters used by the S-ICD to sense the cardiac signals.
. t
i data on S-ICD safety come from the pooled analysis of the U.S. IDE study, the EFFORTLESS
registry [11], and from the midterm outco es analysis of th EFFORTLESS [12]. The pooled analysis
assessed 882 patient during a 651 ± 345 days follow-up [11], while in the extended follow-up of
the EFFORTESS cohort, 985 patients were evaluated with a m an follow-up o 3.1 ± 1.5 years [12].
Moreover, recently published registries analysed the performances of S-ICD in the real world setting
and evaluated in-hospital nd short-term outcomes among thousands of S-ICD recipie ts [13,14].
5.1. Infections
The most common complication associated with S-ICD implants is device infection. The pooled
analysis of the IDE and EFFORTLESS tudies reported a 2% device infection, with 1.7% r quiring
explant/revision [11]. When complications were analysed accordi g to the enrolment period,
a decreasing incidence of i fections with incr asing operator experience as been observ d [15
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which is consistent with a “learning curve”. The resulting reported global infection rate (2.4% over
two years) was comparable to that of TV-ICDs [16,17] (Tables 1 and 2).
Table 1. S-ICD recipients in early as compared with contemporary real-life registries.
EFFORTLESS S-ICD Post Approval Study US S-ICD Trends
N 985 1637 3717
Males 72% 69% 69%
Age (years) 48 ± 17 53 ± 15 53 ± 15
CAD (previous MI) 29% 33% 40%
EF (mean) 43 ± 18 32 ± 14 32 ± 14
Hypertrophic Cardiomiopathy 11% NA 5%
Channelopathies 20% 4% 8%
Diabetes 11% 34% 38.5%
Atrial Fibrillation 16% 16% 20%
CKD 8% 26% (dyalisis 13%) 41% (dyalisis 20%)
CAD: Coronary artery disease; MI: myocardial infarction; EF: ejection fraction; CKD: Chronic kidney disease.
Table 2. Comparison of S-ICD and TV-ICD complications.
Complications SICD TV-ICD Reference
Infections
Infection rate (per year) 2% 1.6% [16–18]
• need for explant 1.7% >50% [19]
• endocarditis/bacteraemia 0% 22–54% [20,21]
Implant Site Complications
Haematoma 4% 0.86–2.4% [5,7,22]
Device erosion 1.2–3% 1.5% [12,23]
Lead or Pulse Generator Complications
Inappropriate shocks (per year) 1.6%
7–10% (first year) [12,24]18% (5 year follow-up)
Electrode dislodgement 0.6% 1.8% (single/dual ICD)5.9% (CRT) [11,12,24]
The results of the midterm analysis of the EFFORTLESS registry are similar: 2.9% of patients had
infection, with 2.4% requiring device explant during a 3.1 years average follow-up [12]. All prosthesis
infections have the potential to become systemic. Indeed, TV-ICD infections are associated with
a 22% to 54% risk of bacteraemia and endocarditis [20,21]. Instead, none of the S-ICD infections
that are reported in the IDE and EFFORTLESS studies resulted in systemic dissemination [25,26].
Trans-venous device infections are unlikely to resolve with antibiotic therapy, and lead extraction
if often required. Common complications of lead extraction include hemopericardium, cardiac
tamponade, pneumothorax, stroke, and vascular damage. Of note, the overall complication rate
in patients undergoing trans-venous lead extraction is higher than previously reported, with mortality
rates exceeding 2% [27].
5.2. Implant Site Complications
Implant-site hematoma and device erosion are less common complications. The incidence of
hematoma was consistently less than 1% across different registries [11–14] (Table 3). Instead, higher
hematoma rates have been reported for TV-ICDs, ranging from 0.86% to 2.4% [5,7,22].
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Table 3. S-ICD complications across prospective studies and real-life registries.
Pooled Analysis IDE +
EFFORTLESS
EFFORTLESS
Midterm
S-ICD Post
Approval Study US S-ICD Trends
Infection requiring removal/revision 1.7% 2.4% 1.2% 0.05%
Erosion 1.2% 1.7%
Hematoma 0.4% 0.9% 0.4% 0.3%
Discomfort 0.9% 0.8% 0.1%
Lead dislodgment 0.6% 0.7% 0.1%
Superficial Infection 0.3% 0.5% 0.1%
Suboptimal PG or/and lead position 1.4% 1.6% 0.5%
Inappropriate shocks: oversensing 4.6% 5.1% 0.2%
Inappropriate shocks: SVTs 2.8% 2.3%
Total complications 9.6% 11.7%
PG: pulse generator, SVT: supraventricular tachycardia.
Device erosion was reported during the early experience, possibly being due to the large first
generation S-ICD and to the implant site in the axilla region. Current rates of erosion are in the range
of 1.2% to 1.8% [11,12] and are consistently decreasing with greater operators experience [15], reduced
dimensions of the new device, and use of the intermuscular implantation technique.
5.3. Lead/Pulse Generator Related Complications
Suboptimal system position was reported in less than 2% of patients, and lead migration is a
rare complication (<1% of patients) [11,12] (Table 3). Of note, even when considering long follow-up
studies [12,28], there are no reported lead malfunctions or failures worldwide. However, as lead
failures typically develop many years after implant, longer-term follow-up is needed to ascertain the
true incidence of S-ICD lead failure.
5.4. Inappropriate Shocks
In the first S-ICD trials, inappropriate shock rate was reported as 5% to 25%, and was mainly
due to supraventricular tachycardia (SVT), T-wave oversensing and lead migration. Careful patient
selection and pre-implantation ECG screening is probably themost effective way to avoid inappropriate
shocks [29]. Exercise testing during pre-implant ECG screening has been suggested [30] and may be
particularly useful in assessing vector eligibility in patients with hypertrophic cardiomyopathy [31,32].
Moreover, post-implant exercise may be used to acquire a new template and to improve discrimination
when heart rate-dependent changes in QRS morphology occur [30], or to optimize vector selection in
patients with specific diseases [33].
Combining careful pre-implant screening and optimized vector selection with enhanced device
programming led to a further reduction in inappropriate S-ICD interventions. Indeed, programming
and discrimination algorithms evolved significantly since the introduction of the S-ICD. Initially,
S-ICDs were programmed with a single 180 bpm shock zone, leading to a high rate of interventions for
sinus tachycardia and other SVTs.
The START (Subcutaneous versus Transvenous Arrhythmia Recognition Testing) trial [8], which
compared discrimination algorithms of S-ICDs and TV-ICDs, reported that adding a conditional VT
zone (dual zone programming) resulted in a 98% specificity for appropriate detection of SVTs for
the S-ICD.
Accordingly, dual zone programming (a 170–220 bpm zone with SVTs discrimination algorithms
plus a zone for heart rate >220 beats/min) significantly decreased the rate of inappropriate shocks [15].
Finally, the introduction of advanced discrimination algorithms and ad-hoc filters that were
designed to avoid T-wave oversensing further decreased the rate of inappropriate shocks [34].
The IDE and EFFORTLESS pooled analysis reported an incidence of inappropriate shock at
3 years of 11.7%, due to SVT (24%) or T-wave oversensing (39%) [11]; similar rates were reported in
the midterm outcomes of the EFFORTLESS registry [12].
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6. Efficacy
6.1. Acute Defibrillation Test
At S-ICD implantion, defibrillation threshold testing (DFT) is typically performed to assess
proper device implantation (i.e., appropriate sensing of ventricular arrhythmia and shock efficacy).
The European clinical trial reported 100% sensitivity for detection of induced VF and 98% shock
efficacy [35]. The midterm analysis of the EFFORTLESS registry [12] reported a failure conversion rate
of 0.2%. DFT was 65 J in 91.6% of patients and 70 to 80 J in 4.4% (3.5% unrecorded energy) [12].
In the S-ICD post approval study [13], DFT testing was performed in the 86.3% of the patients,
with a failure conversion rate of 0.4%. First successful conversion was achieved in 98.7% of the patients
(91.2% 65 J and 7.5% 70 to 80 J). In the US S-ICD Trends [14], DFT testing was performed in 75% of
the patients, reporting a similar high efficacy (92.7% 65 J and 7% 70 to 80 J).
6.2. Spontaneous VT/VF Events
In early longitudinal studies, the S-ICD efficacy in converting spontaneous ventricular arrhythmia
was in the range of 95.2% to 100% [26,35,36].
In the midterm analysis of the EFFORTLESS (994 patients), after a follow-up of 3.1 ± 1.5 years,
a total of 104 patients (10.6%; annual incidence 3.4%) had 278 appropriately treated VT or VF episodes,
including 86 storm episodes. Of non-storm VT or VF episodes, 88.5% were converted with a single
shock and 97.4% (187 of 192 episodes) within five shocks available. All of the patients survived their
arrhythmic events. First shock conversion effectiveness was 90.5% for appropriately treated discrete
episodes of monomorphic ventricular tachycardia (MVT) and 86.6% for polymorphic ventricular
tachycardia (PVT) or VF. Among 13 VT/VF storms, (86 episodes) 12 were successfully converted.
When considering overall shock efficacy, the conversion failure rate was 2.6%. Similar conversion
failure rate was reported for TV-ICDs (2.6% in the SIMPLE trial [37], 1.6% in the NORDIC [38], and
1.6% in the SCD-HeFT [4]).
7. Patient Selection
The S-ICD was approved for the prevention of sudden cardiac death among candidates to an ICD
without indication for anti-bradycardia pacing or CRT, recurrent monomorphic VTs responsive to ATP,
or pre-existing unipolar pacemaker leads. Patients enrolled in early S-ICD prospective registries were
relatively young and with less advanced heart disease [25]. Often, high risk of infections, congenital
heart disease, and poor vascular access were strong determinants of device selection. However,
contemporary S-ICD patients are more severely diseased, older, and have more comorbidities [13,14].
Indeed, in the S-ICD Post-Approval Study [13], the mean age was 53±15 years, 74% of the patients had
heart failure, 34% had diabetes, and 26% had chronic kidney disease. Clinical characteristics of patients
that were enrolled in the recently published US-S-ICD Trends study [14] are similar, patients with
previous myocardial infarction (45%) and low ejection fraction (average 32%) being largely represented
(Table 2). These real-life data are consistent with a shift towards use of S-ICD in contemporary
ICD candidates.
Young patients with cardiomyopathies or channelopathies are ideal candidates for the S-ICD.
Indeed, lead-related complications of the transvenous ICD have been reported to be as high as
2–4% per year in these patients [39,40]. Intravascular lead failure and infection are of outmost
importance in patients with long life-expectancy and low risk of dying from non-arrhythmic causes,
who are those more exposed to long-term complications. Moreover, in patients with inherited primary
electrical diseases (e.g., long and short QT syndrome, catecholaminergic polymorphic VT, Brugada
syndrome, idiopathic VF) the clinical arrhythmia are usually VF or polymorphic VT, which are
unresponsive to ATP. In this regard, the S-ICD was shown to be safe and effective in cardiomyopathy
patients [41,42]. Moreover, because of the small risk of systemic infection [25] and anticipated increased
durability of the lead [23], the S-ICD is an appealing alternative to the TV-ICD in most cardiomyopathy
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patients without a pacing indication. As far as Brugada syndrome is concerned, polymorphic VT
or VF have been consistently shown to be the most common arrhythmia in these patients. Recently,
monomorphic VTs (MVTs) have also been reported in Brugada syndrome patients [43]. However, it
is still unclear whether MVTs in Brugada patients are mechanistically similar to polymorphic VTs,
a distinct disease-related entity, the result of a misclassification bias, or an epiphenomenon [44].
Moreover, while the hypothesis of MVTs as a distinct disease-related entity is intriguing, it is unclear
whether anti-tachycardia pacing may be effective in this specific setting and would balance the
long-term risk of lead-related complications.
8. Conclusions and Perspectives
After almost three decades of innovation in ICD technology, the introduction of an
implantable defibrillator that is radically different in terms of surgical implantation and arrhythmia
detection/discrimination represents a technical and clinical breakpoint in the long fight against sudden
cardiac death. Data from clinical studies support S-ICD efficacy and safety in detecting and terminating
ventricular arrhythmia. While in the early S-ICD experience the ideal candidates were relatively young
and with less advanced heart disease, the paradigm is rapidly shifting towards use of the S-ICD in
contemporary ICD candidates. Indeed, according to current guidelines [45], all ICD candidates have a
class IIa indication for the implantation of an S-ICD unless pacing for bradycardia, anti-tachycardia
pacing, or resynchronization therapy is needed or anticipated. Of note, patients who meet criteria
for an ICD who have inadequate vascular access or are at high risk for infection (including those
with previous TV-ICD infection), and in whom pacing is neither needed nor anticipated, have a class
I indication [45]. As the question whether an S-ICD may be considered completely equivalent to a
TV-ICD in patients without pacing indication is presently unaddressed, the PRAETORIAN trial [46] is
currently randomizing patients to an S-ICD or a TV-ICD and will compare the two devices in terms of
safety and efficacy.
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